Great Science
Deep Compassion
Real Impact
Working together to address addiction,
serious mental illness and cancer.
Featured News
October 18, 2021
Alkermes Announces Commercial Availability of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder
September 22, 2021
New Survey Provides Insights Into Drinking Behaviors During the Pandemic
Responsibility
We champion an approach that views patients holistically and with compassion. Working together with stakeholders across the healthcare community, our team is focused on cutting-edge science, developing innovative medicines and patient-focused advocacy to make a real-world impact in the lives of people living with difficult-to-treat conditions.
Driven by Passion
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
COVID-19 Response
In response to urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our medicines and development products.
Pipeline Preview
We seek to develop treatments that address unmet patient needs in complex and difficult-to-treat diseases in the areas of neuroscience and oncology. Our pipeline is comprised of clinical and preclinical candidates generated from our scientific platforms, including synaptic dysfunction in neuroscience and immune modulation in oncology.
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- FDA-Approved
-
Neuroscience
-
LYBALVI® (olanzapine and samidorphan) - Schizophrenia/Bipolar I Disorder
-
ALKS 1140 - Neurology (Orphan)
-
-
Oncology
-
Nemvaleukin alfa*
-
